Pre-configured to identify normal, high-vibration, and unstable motor conditions STMicroelectronics (NYSE:STM)GENEVA, ...

Designed for M5Stack Atom, AtomS3, and AtomS3R series IoT controllers based on ESP32 or ESP32-S3 wireless SoC, the Echo Pyramid base enables smart voice ...

STMicroelectronics’ new STM32 series redefines entry-level microcontroller performance and value for smart devices everywhereSTM32C5 with ...

When it comes to REITs (XLRE), Agree Realty (ADC) is at the top of the list in terms of quality. Although their recent earnings showed core FFO in line with analysts' estimates, the company saw solid ...

The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. DS3790 is a specifically engineered, ...

Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors. Under current NCCN guidelines as of mid-December 2025, ...

Research-backed strategy produces highly homogeneous antibody-drug conjugates (gsADCs) with consistent DAR and tumor suppression lasting over 50 days after a single dose A new white paper from ...

stm32_adc_dma_uart/ ├── src/ │ ├── startup_stm32f401_gcc.s # ARM Cortex-M4 startup code │ ├── system_stm32f4xx.c # System clock initialization (PLL configuration) │ └── main.c # Main firmware (all ...

A billboard that popped up in Times Square proclaiming “Jesus is Palestinian” was slammed by onlookers as an inflammatory and divisive prop that does nothing more than “stir the pot” at Christmas. The ...

Enhertu, a targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo, may now be used as a first-line treatment for advanced cases of breast cancer, making it the first new approved ...

Antibody drug conjugates (ADCs) mark a new era in targeted cancer therapy, delivering potent cytotoxic chemotherapy via monoclonal antibodies directly into the tumor cells — an era with potentially ...

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients. DB-1305/BNT325, a TROP2-targeted antibody ...